Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Seattle Genetics begins phase I study of SGN-LIV1A

Oct. 22, 2013

Team of Japanese researchers designs novel antibodies for multiple myeloma

Oct. 22, 2013

Phase Ia VGX-100 trial completes patient enrollment

Oct. 18, 2013

Lytix Biopharma receives clearance to conduct phase I study of LTX-315

Oct. 17, 2013

A priming dendritic cell-based vaccine confers broad-spectrum antitumor immunity

Oct. 17, 2013

Evaluation of antibody-based delivery of IL-2 for the treatment of blood cancers

Oct. 17, 2013

Cel-Sci and Ergomed sign deal for Multikine

Oct. 16, 2013

Novel photoimmunoconjugates discovered by German group

Oct. 15, 2013

OncoTherapy Science presents phase II results for OTS-102 in biliary tract cancer

Oct. 11, 2013

Molecular Templates raises funds to advance MT-3724

Oct. 10, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...